Literature DB >> 19118375

Treatment of acute myeloid leukemia.

Elihu H Estey1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19118375      PMCID： PMC2625419          DOI： 10.3324/haematol.2008.001263

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  28 in total

1.  New designs for phase 2 clinical trials.

Authors:  Elihu H Estey; Peter F Thall
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

2.  The effect of chemotherapy on acute leukemia in the human.

Authors:  E J FREIREICH; E A GEHAN; D SULMAN; D R BOGGS; E FREI
Journal:  J Chronic Dis       Date:  1961-12

3.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Authors:  Hagop Kantarjian; Yasuhiro Oki; Guillermo Garcia-Manero; Xuelin Huang; Susan O'Brien; Jorge Cortes; Stefan Faderl; Carlos Bueso-Ramos; Farhad Ravandi; Zeev Estrov; Alessandra Ferrajoli; William Wierda; Jianqin Shan; Jan Davis; Francis Giles; Hussain I Saba; Jean-Pierre J Issa
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

4.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

Authors:  D Grimwade; H Walker; G Harrison; F Oliver; S Chatters; C J Harrison; K Wheatley; A K Burnett; A H Goldstone
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

5.  Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.

Authors:  M de Lima; S S Strom; M Keating; H Kantarjian; S Pierce; S O'Brien; E Freireich; E Estey
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

6.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Authors:  Lewis R Silverman; David R McKenzie; Bercedis L Peterson; James F Holland; Jay T Backstrom; C L Beach; Richard A Larson
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

Review 7.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

8.  Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia.

Authors:  E Estey; T L Smith; M J Keating; K B McCredie; E A Gehan; E J Freireich
Journal:  Leukemia       Date:  1989-04       Impact factor: 11.528

9.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Authors:  D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

10.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Authors:  C D Bloomfield; D Lawrence; J C Byrd; A Carroll; M J Pettenati; R Tantravahi; S R Patil; F R Davey; D T Berg; C A Schiffer; D C Arthur; R J Mayer
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701
View more
  17 in total

1.  Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).

Authors:  Sergio Amadori; Stefan Suciu; Dominik Selleslag; Roberto Stasi; Giuliana Alimena; Liliana Baila; Vittorio Rizzoli; Erika Borlenghi; Gianluca Gaidano; Domenico Magro; Giuseppe Torelli; Petra Muus; Adriano Venditti; Emma Cacciola; Francesco Lauria; Marco Vignetti; Theo de Witte
Journal:  Br J Haematol       Date:  2010-03-08       Impact factor: 6.998

Review 2.  Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.

Authors:  Alison Walker; Guido Marcucci
Journal:  Expert Rev Hematol       Date:  2012-10       Impact factor: 2.929

Review 3.  Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.

Authors:  Shaheedul A Sami; Noureldien H E Darwish; Amanda N M Barile; Shaker A Mousa
Journal:  Curr Treat Options Oncol       Date:  2020-01-13

Review 4.  MicroRNA expression in acute myeloid leukemia.

Authors:  Guido Marcucci; Michael D Radmacher; Krzysztof Mrózek; Clara D Bloomfield
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

5.  Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors.

Authors:  Pia Riemke; Melinda Czeh; Josephine Fischer; Carolin Walter; Saeed Ghani; Matthias Zepper; Konstantin Agelopoulos; Stephanie Lettermann; Marie L Gebhardt; Nancy Mah; Andre Weilemann; Michael Grau; Verena Gröning; Torsten Haferlach; Dido Lenze; Ruud Delwel; Marco Prinz; Miguel A Andrade-Navarro; Georg Lenz; Martin Dugas; Carsten Müller-Tidow; Frank Rosenbauer
Journal:  EMBO J       Date:  2016-08-29       Impact factor: 11.598

6.  Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy.

Authors:  John L Vaughn; David Kline; Nathan M Denlinger; Leslie A Andritsos; Matthew C Exline; Alison R Walker
Journal:  Leuk Lymphoma       Date:  2017-09-13

7.  Challenges in treating older patients with acute myeloid leukemia.

Authors:  Lagadinou D Eleni; Zoumbos C Nicholas; Spyridonidis Alexandros
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

8.  Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.

Authors:  A Mims; A R Walker; X Huang; J Sun; H Wang; R Santhanam; A M Dorrance; C Walker; P Hoellerbauer; S S Tarighat; K K Chan; R B Klisovic; D Perrotti; M A Caligiuri; J C Byrd; C-S Chen; L James Lee; S Jacob; K Mrózek; C D Bloomfield; W Blum; R Garzon; S Schwind; G Marcucci
Journal:  Leukemia       Date:  2012-11-26       Impact factor: 11.528

9.  A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.

Authors:  Francesca Chiarini; Annalisa Lonetti; Gabriella Teti; Ester Orsini; Daniela Bressanin; Alessandra Cappellini; Francesca Ricci; Pier Luigi Tazzari; Andrea Ognibene; Mirella Falconi; Pasqualepaolo Pagliaro; Ilaria Iacobucci; Giovanni Martinelli; Sergio Amadori; James A McCubrey; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-12

10.  Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia.

Authors:  Jean Carlos Lipreri da Silva; Juan Luiz Coelho-Silva; Keli Lima; Hugo Passos Vicari; Mariana Lazarini; Leticia Veras Costa-Lotufo; Fabiola Traina; João Agostinho Machado-Neto
Journal:  Cell Oncol (Dordr)       Date:  2021-07-01       Impact factor: 6.730
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.